Literature DB >> 31665341

Varicella-Zoster Virus Infection of Primary Human Spinal Astrocytes Produces Intracellular Amylin, Amyloid-β, and an Amyloidogenic Extracellular Environment.

Andrew N Bubak1, Christina N Como1, Christina M Coughlan1,2,3, Noah R Johnson1,2,3, James E Hassell1, Teresa Mescher1, Christy S Niemeyer1, Ravi Mahalingam1, Randall J Cohrs1,4, Timothy D Boyd1,2,3, Huntington Potter1,2,3, Holger A Russ5, Maria A Nagel1,6.   

Abstract

BACKGROUND: Herpes zoster is linked to amyloid-associated diseases, including dementia, macular degeneration, and diabetes mellitus, in epidemiological studies. Thus, we examined whether varicella-zoster virus (VZV)-infected cells produce amyloid.
METHODS: Production of intracellular amyloidogenic proteins (amylin, amyloid precursor protein [APP], and amyloid-β [Aβ]) and amyloid, as well as extracellular amylin, Aβ, and amyloid, was compared between mock- and VZV-infected quiescent primary human spinal astrocytes (qHA-sps). The ability of supernatant from infected cells to induce amylin or Aβ42 aggregation was quantitated. Finally, the amyloidogenic activity of viral peptides was examined.
RESULTS: VZV-infected qHA-sps, but not mock-infected qHA-sps, contained intracellular amylin, APP, and/or Aβ, and amyloid. No differences in extracellular amylin, Aβ40, or Aβ42 were detected, yet only supernatant from VZV-infected cells induced amylin aggregation and, to a lesser extent, Aβ42 aggregation into amyloid fibrils. VZV glycoprotein B (gB) peptides assembled into fibrils and catalyzed amylin and Aβ42 aggregation.
CONCLUSIONS: VZV-infected qHA-sps produced intracellular amyloid and their extracellular environment promoted aggregation of cellular peptides into amyloid fibrils that may be due, in part, to VZV gB peptides. These findings suggest that together with host and other environmental factors, VZV infection may increase the toxic amyloid burden and contribute to amyloid-associated disease progression.
© The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  Alzheimer disease; Aβ42; amylin; amyloid; astrocytes; varicella-zoster virus

Year:  2020        PMID: 31665341      PMCID: PMC7075411          DOI: 10.1093/infdis/jiz560

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  42 in total

1.  Gastric amylin expression. Cellular identity and lack of requirement for the homeobox protein PDX-1. A study in normal and PDX-1-deficient animals with a cautionary note on antiserum evaluation.

Authors:  J E Tingstedt; H Edlund; O D Madsen; L I Larsson
Journal:  J Histochem Cytochem       Date:  1999-08       Impact factor: 2.479

2.  Amylin deposition in the brain: A second amyloid in Alzheimer disease?

Authors:  Kaleena Jackson; Gustavo A Barisone; Elva Diaz; Lee-way Jin; Charles DeCarli; Florin Despa
Journal:  Ann Neurol       Date:  2013-07-12       Impact factor: 10.422

3.  Amylin as a growth factor during fetal and postnatal development of the rat kidney.

Authors:  P J Wookey; C Tikellis; M Nobes; D Casley; M E Cooper; I A Darby
Journal:  Kidney Int       Date:  1998-01       Impact factor: 10.612

4.  In vivo seeding and cross-seeding of localized amyloidosis: a molecular link between type 2 diabetes and Alzheimer disease.

Authors:  Marie E Oskarsson; Johan F Paulsson; Sebastian W Schultz; Martin Ingelsson; Per Westermark; Gunilla T Westermark
Journal:  Am J Pathol       Date:  2015-02-17       Impact factor: 4.307

5.  Amylin, released from the gastric fundus, stimulates somatostatin and thus inhibits histamine and acid secretion in mice.

Authors:  Muhammad Zaki; Shashi Koduru; Robert McCuen; Lokesh Vuyyuru; Mitchell L Schubert
Journal:  Gastroenterology       Date:  2002-07       Impact factor: 22.682

6.  Zoster myelitis: improvement with antiviral therapy in two cases.

Authors:  S M de Silva; A S Mark; D H Gilden; R Mahalingam; M Balish; F Sandbrink; S Houff
Journal:  Neurology       Date:  1996-10       Impact factor: 9.910

7.  Reduced nociceptive behavior in islet amyloid polypeptide (amylin) knockout mice.

Authors:  S Gebre-Medhin; H Mulder; Y Zhang; F Sundler; C Betsholtz
Journal:  Brain Res Mol Brain Res       Date:  1998-12-10

8.  Herpes Zoster and Dementia: A Nationwide Population-Based Cohort Study.

Authors:  Yao-Hsu Yang; Kuan-Lun Huang; Vincent Chin-Hung Chen; Shu-I Wu; Kuo-You Huang; Ting-Yu Kuo; Hsin-Yi Liang; Michael Gossop
Journal:  J Clin Psychiatry       Date:  2018 Jan/Feb       Impact factor: 4.384

9.  Varicella-Zoster Virus and the Enteric Nervous System.

Authors:  Michael Gershon; Anne Gershon
Journal:  J Infect Dis       Date:  2018-09-22       Impact factor: 5.226

10.  Risk and impact of herpes zoster on patients with diabetes: A population-based study, 2009-2014.

Authors:  Cintia Muñoz-Quiles; Mónica López-Lacort; F Javier Ampudia-Blasco; Javier Díez-Domingo
Journal:  Hum Vaccin Immunother       Date:  2017-11-02       Impact factor: 3.452

View more
  15 in total

1.  Acute zoster plasma contains elevated amyloid, correlating with Aβ42 and amylin levels, and is amyloidogenic.

Authors:  Andrew N Bubak; Cheryl Beseler; Christina N Como; Stephen K Tyring; Christopher Haley; Teresa Mescher; James E Hassell; Randall J Cohrs; Huntington Potter; Maria A Nagel
Journal:  J Neurovirol       Date:  2020-05-08       Impact factor: 2.643

2.  Incident Herpes Zoster and Risk of Dementia: A Population-Based Danish Cohort Study.

Authors:  Sigrun Alba Johannesdottir Schmidt; Katalin Veres; Henrik Toft Sørensen; Niels Obel; Victor W Henderson
Journal:  Neurology       Date:  2022-06-08       Impact factor: 11.800

Review 3.  Neurology and the COVID-19 Pandemic: Gathering Data for an Informed Response.

Authors:  Brigit High; Alison M Hixon; Kenneth L Tyler; Amanda L Piquet; Victoria S Pelak
Journal:  Neurol Clin Pract       Date:  2021-04

4.  Detection of varicella zoster virus antigen and DNA in two cases of cerebral amyloid angiopathy.

Authors:  Teresa Mescher; Philip J Boyer; Andrew N Bubak; James E Hassell; Maria A Nagel
Journal:  J Neurol Sci       Date:  2021-01-09       Impact factor: 3.181

5.  Cognitive impairment without altered levels of cerebrospinal fluid biomarkers in patients with encephalitis caused by varicella-zoster virus: a pilot study.

Authors:  Marie Eckerström; Staffan Nilsson; Henrik Zetterberg; Kaj Blennow; Anna Grahn
Journal:  Sci Rep       Date:  2020-12-28       Impact factor: 4.379

6.  Amylin, Aβ42, and Amyloid in Varicella Zoster Virus Vasculopathy Cerebrospinal Fluid and Infected Vascular Cells.

Authors:  Andrew N Bubak; Cheryl Beseler; Christina N Como; Christina M Coughlan; Noah R Johnson; James E Hassell; Anna M Burnet; Teresa Mescher; D Scott Schmid; Colin Coleman; Ravi Mahalingam; Randall J Cohrs; Timothy D Boyd; Huntington Potter; Ali H Shilleh; Holger A Russ; Maria A Nagel
Journal:  J Infect Dis       Date:  2021-04-08       Impact factor: 5.226

Review 7.  Some Candidate Drugs for Pharmacotherapy of Alzheimer's Disease.

Authors:  Barbara Miziak; Barbara Błaszczyk; Stanisław J Czuczwar
Journal:  Pharmaceuticals (Basel)       Date:  2021-05-13

Review 8.  Mechanisms and therapeutic potential of interactions between human amyloids and viruses.

Authors:  Emiel Michiels; Frederic Rousseau; Joost Schymkowitz
Journal:  Cell Mol Life Sci       Date:  2020-11-26       Impact factor: 9.261

9.  Cerebral Fructose Metabolism as a Potential Mechanism Driving Alzheimer's Disease.

Authors:  Richard J Johnson; Fernando Gomez-Pinilla; Maria Nagel; Takahiko Nakagawa; Bernardo Rodriguez-Iturbe; Laura G Sanchez-Lozada; Dean R Tolan; Miguel A Lanaspa
Journal:  Front Aging Neurosci       Date:  2020-09-11       Impact factor: 5.750

10.  Herpesvirus infections, antiviral treatment, and the risk of dementia-a registry-based cohort study in Sweden.

Authors:  Karin Lopatko Lindman; Eva-Stina Hemmingsson; Bodil Weidung; Jon Brännström; Maria Josefsson; Jan Olsson; Fredrik Elgh; Peter Nordström; Hugo Lövheim
Journal:  Alzheimers Dement (N Y)       Date:  2021-02-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.